| Abstrakt: |
The patent application titled "Recombinant Proteinaceous Binding Molecules" discusses the development of bispecific antibodies and chimeric antigen receptor (CAR) T cells for cancer immunotherapy. It explains that bispecific antibodies have two binding sites and can recruit cytotoxic T cells to target tumors, while CAR T cells are genetically modified to target tumor antigens. Both have shown promise in clinical trials, but there are limitations. The application describes a recombinant proteinaceous binding molecule that combines a binding moiety, antibody variable domain, and altered Fc fragment to enhance binding capabilities. This molecule has potential therapeutic applications, particularly in cancer treatment. [Extracted from the article] |
